Personalized immunotherapy against several neuronal and brain tumors

Abstract

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

1 . A composition comprising a peptide consisting of the amino acid sequence FLVDGSWSI (SEQ ID NO: 28) and an adjuvant. 
     
     
         2 . The composition of  claim 1 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. 
     
     
         3 . The composition of  claim 2 , wherein the adjuvant is IL-1. 
     
     
         4 . The composition of  claim 2 , wherein the adjuvant is IL-2. 
     
     
         5 . The composition of  claim 2 , wherein the adjuvant is IL-4. 
     
     
         6 . The composition of  claim 2 , wherein the adjuvant is IL-7. 
     
     
         7 . The composition of  claim 2 , wherein the adjuvant is IL-12. 
     
     
         8 . The composition of  claim 2 , wherein the adjuvant is IL-13. 
     
     
         9 . The composition of  claim 2 , wherein the adjuvant is IL-15. 
     
     
         10 . The composition of  claim 2 , wherein the adjuvant is IL-21. 
     
     
         11 . The composition of  claim 2 , wherein the adjuvant is IL-23. 
     
     
         12 . The composition of  claim 1 , further comprising a pharmaceutically acceptable carrier. 
     
     
         13 . The composition of  claim 12 , wherein the pharmaceutically acceptable carrier is selected from saline, Ringer's solution, dextrose solution, and sustained release preparation. 
     
     
         14 . The composition of  claim 1 , further comprising a pharmaceutically acceptable excipient. 
     
     
         15 . The composition of  claim 14 , wherein said pharmaceutically acceptable excipient is selected from buffer, diluent, flavor, and lubricant. 
     
     
         16 . The composition of  claim 1 , wherein the peptide is in the form of a pharmaceutically acceptable salt. 
     
     
         17 . The composition of  claim 16 , wherein the pharmaceutically acceptable salt is chloride salt. 
     
     
         18 . The composition of  claim 16 , wherein the pharmaceutically acceptable salt is acetate salt. 
     
     
         19 . The composition of  claim 16 , wherein the pharmaceutically acceptable salt is trifluoro-acetate salt. 
     
     
         20 . The composition of  claim 1 , wherein the composition is a pharmaceutical composition and further comprises water and a buffer.